gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VIVSHealthcareBiotechnology

VivoSim Labs, Inc. Common Stock (VIVS)

$0.1522+5.99%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.15▼ 93.08% in range
Nov 4, 2025Low $0.14 · High $2.92Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

VivoSim Labs closed at $0.15 on Nov 4, up 5.99%, 94.8% below its 52-week closing high. Volume of 540.9K shares was 0.49× its 20-day average (below normal).

Split-adjusted performance: -24.6% over one month, -89.2% over six months, -93.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $18K, down 51.4% from a year earlier, with a net margin of -7433.3%.

Short interest was 598.4K shares at the Oct 15 settlement, down 15.5% from the prior report (4.0% of float, 1.0 days to cover).

Market cap$2.0M13.4M shares
Revenue · quarter$18.0K−51.4% YoY
Diluted EPS$-0.25—
P/E · TTM—P/S 18.2×
Net margin-7,433.3%Gross 100.0%
Dividend yieldNone
52-week range0.14 – 2.92−94.8% from high
Volume540.9K0.49× 20-day avg
Volatility · 60d77.2%Annualised
Short % of float4.0%1.0 days to cover
Net cash$1.7MCash $1.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.5%1M −24.6%3M −53.9%6M −89.2%YTD −91.6%1Y −93.6%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum2
Revenue growth22
Net margin12
Value (low P/E)—
Size1

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short598.4K−15.5% vs prior
Days to cover1.0Settled Oct 15
% of float4.0%
Short vol. 10d40.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VIVSVivoSim Labs$0.1522+5.99%−89.2%−51.4%−7433.3%—$2.0M
CLDICalidi Biotherapeutics$0.7299−2.54%−79.3%———$1.9MCompare
SLXNSilexion Therapeutics$0.1535+0.10%−97.3%———$2.2MCompare
CRISCuris$1.11+55.48%−91.0%−100.0%——$2.7MCompare
HLSQTessera Defense and Homeland Security$0.1440−1.57%————$3.0MCompare
LIMNLiminatus Pharma$2.79+0.16%−72.7%———$3.8MCompare
PMCBPharmaCyte Biotech$0.3810+12.03%−50.5%———$4.1MCompare
CELZCreative Medical Technology Holdings$0.6519−3.21%−70.8%———$4.9MCompare
AIMAIM ImmunoTech$0.1610+0.19%−66.5%+4.0%−26876.9%—$6.4MCompare

News about VivoSim Labs

All news →

No recent articles focused on VivoSim Labs.

Quick answers

What does VivoSim Labs do?
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development.
What is VIVS's market cap?
$2.04M, based on the Nov 4 close of $0.15.
Does VivoSim Labs pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VIVS is sold short?
598.4K shares, 4.0% of float, as of Oct 15, 2026.
What sector is VIVS in?
Healthcare, in the Biotechnology industry.

About VivoSim Labs

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

HQ: San Diego, CA11 employeesListed Aug 16, 2011organovo.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology